Download - Clinical trial in special population final
![Page 1: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/1.jpg)
BATCH 1
MONISHA MOHANANUPAM
PGD ACR - V
![Page 2: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/2.jpg)
� The Pediatric Rule requires drug makers of
selected new and existing drugs to conduct
studies on drug safety and effectiveness in
children.s The Best Pharmaceuticals for Children Act,
in exchange for studying the drug in children, the
drug maker gets six months of selling their
product without competition.
![Page 3: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/3.jpg)
3. The Pediatric Research Equity Act
gives FDA the right to ask drug companies
to study the effectiveness of new drugs in
children.
![Page 4: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/4.jpg)
The paediatric studies should include –
(a)Clinical trials,
(b) Relative bioequivalence comparisons of the paediatric formulation with the adult formulation performed in adults, and
(c) Definitive pharmacokinetic studies for dose
selection across the age ranges of paediatric patients in whom the drug is likely to be used. These studies should be conducted in the paediatric patient population with the disease under study.
![Page 5: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/5.jpg)
E 11- Clinical investigation of medicinal products in the pediatric population
![Page 6: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/6.jpg)
![Page 7: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/7.jpg)
Preterm newborn infants
Term newborn infants (0 to 27 days)
Infants and toddlers (28 days to 23 months)
Children (2 to 11 years) Adolescents (12 to 16-18 years (dependent on region))
![Page 8: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/8.jpg)
![Page 9: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/9.jpg)
Unique pathophysiology and responses
to therapy
The category of preterm newborn
infants is not a homogeneous group of
patients. A 25-week gestation, 500-gram (g) newborn is very different from a
30-week gestation newborn weighing 1,500 g. A distinction should also be made for low-birth-weight babies as to
whether they are immature or growth retarded.
![Page 10: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/10.jpg)
![Page 11: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/11.jpg)
Gestational age at birth and age after birth (adjusted age)
Immaturity of renal and hepatic clearance mechanisms
Penetration of medicinal products into the central nervous system (CNS)
Unique neonatal disease states (e.g., Respiratory distress syndrome of the newborn, patent ductus arteriosus, primary pulmonary hypertension);
![Page 12: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/12.jpg)
Unique susceptibilities of the preterm newborn (e.g., Necrotizing enterocolitis, intraventricular hemorrhage)
Transdermal absorption of medicinal products and other chemicals.
![Page 13: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/13.jpg)
(1) weight and age (gestational and postnatal) stratification
(2) small blood volumes (a 500-g infant has 40 mL of blood)
(3) small numbers of patients at a
given center and differences in care among centers
![Page 14: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/14.jpg)
Term newborn infants are developmentally more mature than preterm newborn infants
Volumes of distribution of medicinal products may be different from those in older pediatric patients because of different body water and fat content.
The blood-brain barrier is still not fully mature and medicinal products and endogenous substances (e.g., bilirubin) may gain access to the CNS with resultant toxicity.
![Page 15: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/15.jpg)
Hepatic and renal clearance mechanisms are immature and rapidly changing; doses may need to be adjusted over the first weeks of life.
Increased susceptibility to toxic effects of medicinal products result from limited clearance in these patients (e.g., chloramphenicol grey baby syndrome).
On the other hand, term newborn infants may be less susceptible to some types of adverse effects (e.g., aminoglycoside nephrotoxicity) than are patients in older age groups.
![Page 16: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/16.jpg)
This is a period of rapid CNS maturation, immune system development and total body growth.
Oral absorption becomes more reliable.
Hepatic and renal clearance pathways continue to mature rapidly.
By 1 to 2 years of age, clearance of many drugs on a mg/kg basis may exceed adult values.
The developmental pattern of maturation is
dependent on specific pathways of clearance. There is often considerable inter-individual variability in maturation.
![Page 17: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/17.jpg)
![Page 18: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/18.jpg)
Most pathways of drug clearance (hepatic and renal) are mature, with clearance often exceeding adult values.
- maturation of specific metabolic pathways.
Children achieve several important milestones of psychomotor development that could be adversely affected by CNS-active drugs.
![Page 19: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/19.jpg)
Highly variable and occurs earlier in girls.
Puberty can affect the apparent activity of enzymes that metabolize drugs, and dose requirements for some medicinal products on a mg/kg basis may decrease dramatically (e.g., theophylline).
In some cases, it may be appropriate to specifically assess the effect of puberty on a medicinal product by studying pre- and postpubertal pediatric patients.
In other cases, it may be appropriate to record Tanner stages of pubertal development or obtain biological markers of puberty and examine data for any potential influence of pubertal changes.
![Page 20: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/20.jpg)
Specific strategies should be addressed in protocols to ascertain any effects of the medicinal product on growth and development.
Stratification by age within this category is often unnecessary, but it may be appropriate to stratify patients based on pharmacokinetic and/or efficacy endpoint considerations.
![Page 21: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/21.jpg)
This is a period of sexual maturation; medicinal products may interfere with the actions of sex hormones and impede development.
In certain studies, pregnancy testing and review of sexual activity and contraceptive use may be appropriate.
Medicinal products and illnesses that delay or accelerate the onset of puberty can have a profound effect on the pubertal growth spurt and, by changing the pattern of growth, may affect final height.
![Page 22: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/22.jpg)
Evolving cognitive and emotional changes could potentially influence the outcome of clinical studies.
Many diseases are also influenced by the hormonal changes around puberty (e.g., increases in insulin resistance in diabetes mellitus, recurrence of seizures around menarche, changes in the frequency and severity of migraine attacks and asthma exacerbations).
Hormonal changes may thus influence the results of clinical studies.
![Page 23: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/23.jpg)
The toxicity of some excipients may vary across pediatric
age groups and between pediatric and adult populations,
e.g., benzyl alcohol is toxic in the preterm newborn.
Depending on the active substance and excipients,
appropriate use of the medicinal product in the newborn
may require a new formulation or appropriate information
about dilution of an existing formulation.
![Page 24: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/24.jpg)
The volume of blood withdrawn should be
minimized in pediatric studies.
Blood volumes should be justified in protocols.
IRB’s/IEC’s review and may define the maximum
amount of blood (usually on a milliliters (mL)/kg
or percentage of total blood volume basis) that
may be taken for investigational purposes.
![Page 25: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/25.jpg)
The number and type of assays and investigations should
take into consideration based on the age and/or
bodyweight (body surface area if appropriate) of the
children to be included in the trial.
Use of sensitive assays for parent drugs and metabolites
to decrease the volume of blood required per sample
For blood and tissue assays, microvolumes and micro-
assays should be used, whenever possible
![Page 26: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/26.jpg)
Use of laboratories- experienced in handling
small volumes of blood for pharmacokinetic
analyses and for laboratory safety studies
(blood counts, clinical chemistry)
Sampling should be performed by trained
staff. The number of attempts for sampling
should be limited.
![Page 27: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/27.jpg)
Collection of routine, clinical blood samples wherever
possible at the same time as samples are obtained for
pharmacokinetic analysis .
Alternative sampling (e.g. urine or salvia sampling) for
pharmacokinetic studies should be preferred when
possible.
- In principle, general and / or local anaesthesia should be used as
appropriate for painful and/or invasive procedures.
![Page 28: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/28.jpg)
Timing of sampling should be co-ordinated as far as
possible to avoid repeated procedures and sampling
during the day in order to minimize pain and distress,
and the risk of iatrogenic complications.
Timing of sampling and number of sampling attempts
should be defined in the protocol. For example, it is
recommended that after one unsuccessful attempt,
another experienced person take over the procedure.
![Page 29: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/29.jpg)
The use of indwelling catheters, etc., to minimize distress
Use of population pharmacokinetics and sparse sampling
based on optimal sampling theory to minimize the number of
samples obtained from each patient. Techniques include:
Sparse sampling approaches where each patient contributes
as few as 2 to 4 observations at predetermined times to an
overall “population area-under-the-curve”
i Population pharmacokinetic analysis using the most useful
sampling time points derived from modeling of adult data
![Page 30: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/30.jpg)
Preterm and term neonates have very limited blood
volume, are often anaemic due to age and frequent
sampling related to pathological conditions.
The fact that children, especially in this age group,
receive blood transfusions (or iron or erythropoietin
supplementation) should not be used as a convenience
for increased volume or frequency for blood sampling.
![Page 31: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/31.jpg)
Per individual, the trial-related blood loss (including any losses in
the manoeuvre) should not exceed 3 % of the total blood volume
during a period of four weeks and should not exceed 1% at any
single time.
In the rare case of simultaneous trials, the recommendation of 3%
remains the maximum.
Monitoring of actual blood loss is routinely required in preterm
and term neonates.
![Page 32: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/32.jpg)
When a medicinal product is studied in
pediatric patients in one region, the
intrinsic (e.g., pharmacogenetic) and
extrinsic (e.g., diet) factors that could
impact on the extrapolation of data to
other regions should be considered.
![Page 33: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/33.jpg)
Obtaining knowledge of the effects of medicinal
products in pediatric patients is an important
goal. However, this should be done without
compromising the well-being of pediatric patients
participating in clinical studies.
![Page 34: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/34.jpg)
Benefits and discomforts should be described in the level of the child’s understanding
A child >7yrs of age should give consent by signing the assent form
One or both the parents should give consent based on the extent of risk of the trial
![Page 35: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/35.jpg)
Assent and age
Parental consent will probably be invalid if it is given against the child’s interests.
Consent process in emergency
![Page 36: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/36.jpg)
Parental understanding of randomisation
Enrolling patients in multiple trialsEnrolling children in phase I studies
avoidedFactors affecting informed consent -
diff of opinion, personal benefit,
![Page 37: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/37.jpg)
Pharmacokinetic studyEfficacy studiesSafety studiesCohort studyCase–control studies
![Page 38: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/38.jpg)
Open protocol designOpen label trialsHistorical controlBayesian designed trialsCrossover designSurrogate end-pointUnderpowered studies
![Page 39: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/39.jpg)
Children not involved if the study can be done with adults
It should be to obtain knowledgeParent or Legal guardian – Proxy
ConsentAssentsAdequate medical supportRefusal respected
![Page 40: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/40.jpg)
EU Regulation on paediatric medicinesThe EU Regulation on Paediatric Medicines1 was adopted on 12 December 2006 and came into force on 26 January 2007.
![Page 41: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/41.jpg)
increased availability of medicines specifically adapted and licensed for use in the paediatric population
increased information available to the patient and prescriber about the use of medicines in children, including clinical trial data
increase in high quality research into medicines for children.
![Page 42: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/42.jpg)
BACKGROUND Lamivudine therapy is effective for
chronic hepatitis B infection in adults. We evaluated the efficacy and tolerability of lamivudine as a treatment for chronic infection with hepatitis B virus (HBV) in children.
![Page 43: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/43.jpg)
Children with chronic hepatitis B were randomly assigned in a 2:1 ratio to receive either oral lamivudine (3 mg per kilogram of body weight; maximum, 100 mg) or placebo once daily for 52 weeks. The primary end point was virologic response (defined by the absence of serum hepatitis B e antigen and serum HBV DNA) at week 52 of treatment.
![Page 44: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/44.jpg)
Of the 403 children screened, 191 were randomly assigned to receive lamivudine and 97 to receive placebo. The rate of virologic response at week 52 was higher among children who received lamivudine than among those who received placebo (23 percent vs. 13 percent, P=0.04). Lamivudine therapy was well tolerated and was also associated with higher rates of seroconversion from hepatitis B e antigen to hepatitis B e antibody, normalization of alanine aminotransferase levels, and suppression of HBV DNA.
![Page 45: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/45.jpg)
CONCLUSIONS In children with chronic hepatitis B, 52
weeks of treatment with lamivudine was associated with a significantly higher rate of virologic response than the placebo
![Page 46: Clinical trial in special population final](https://reader033.vdocuments.us/reader033/viewer/2022060123/559710271a28ab59708b45ff/html5/thumbnails/46.jpg)
?